With significant reductions in cataplexy attacks, enhanced cognition and long-term safety demonstrated in the ENCORE Phase III trial, Axsome Therapeutics’ AXS-12 (reboxetine) brings immense potential. Read more at https://buff.ly/4g9S6ys by Soumya Shashikumar.
